Drugs / GNS-3545
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07225296 | Nov 2025 → Jun 2026 | idiopathic pulmonary fibrosis | Genosco Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GNS-3545 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07225296 ↗ |
| Route | Oral | “GNS-3545 will be administered as oral tablets” NCT07225296 ↗ |